Biosergen publishes interim report for first quarter 2023
Monday, August 14, 2023: Biosergen AB (“Biosergen” or the “Company”) thereby publishes the interim report for the second quarter 2023. The interim report is available as an attached document and on the company website (www.biosergen.net)
Summary of the Interim Report for Q2 2023
| 2023 | 2022 | 2023 | 2022 | 2022 | |
| TSEK | April-June | April-June | Jan-June | Jan-June | Jan-Dec |
| Profit/loss | |||||
| Other income | 2.456 | 1.409 | 7.771 | 2.726 | 5.183 |
| Profit/loss before depreciation (EBITDA | -8.038 | -7.963 | -13.067 | -12.981 | -34.129 |
| Operating profit/loss befor net financials | -8.038 | -7.963 | -13.067 | -12.981 | -34.129 |
| Net financials | 7 | 3 | 9 | 6 | 81 |
| Netprofit/loss for the period | -8.031 | -7.960 | -13.058 | -12.975 | -34.048 |
| Earnings per share (SEK) | -0,19 | -0,28 | -0,31 | -0,46 | -1,09 |
Highlights during Q2 2023
- March 29, Biosergen provides Phase 2 clinical development strategy update.
Highlights after the period
- August 7, Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11)
The Financial report can be found on our website: https://biosergen.net/investors/filings